Printer Friendly

BOEHRINGER INGELHEIM PRESIDENT AND CEO DEPARTS

 BOEHRINGER INGELHEIM PRESIDENT AND CEO DEPARTS
 RIDGEFIELD, Conn., June 22 /PRNewswire/ -- Boehringer Ingelheim


Corporation announced today the departure of Digby W. Barrios, president and CEO, effective this date. He was also president and chief operating officer of Boehringer Ingelheim Pharmaceuticals, Inc.
 The board of directors has appointed Werner Gerstenberg, executive vice president and chief financial officer of the corporation, as acting president and CEO of Boehringer Ingelheim Corporation, and acting president and COO of Boehringer Ingelheim Pharmaceuticals, Inc.
 The board, in making the announcement, cited philosophical differences with Barrios about the strategic direction of the corporation. The company has initiated immediate steps to select a successor.
 It was also announced that A. James Ueberroth, senior vice president-operations of Boehringer Ingelheim Pharmaceuticals, Inc., will leave the company on this date.
 -0- 6/22/92
 /CONTACT: David W. Nurnberger of Boehringer Ingelheim, 203-798-4700/ CO: Boehringer Ingelheim Corporation ST: Connecticut IN: MTC SU: PER


PS-LR -- NY072 -- 2606 06/22/92 17:46 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1992
Words:160
Previous Article:AMERICAN SOFTWARE TO DELIVER ENTERPRISE CLASS OPEN SYSTEMS SOFTWARE
Next Article:U.S. EPA, STATE EXTEND PUBLIC COMMENT PERIOD ON DOW INCINERATOR


Related Articles
WERNER GERSTENBERG APPOINTED PRESIDENT, CHIEF EXECUTIVE OFFICER OF BOEHRINGER INGELHEIM CORPORATION
CAMBRIDGE NEUROSCIENCE AND BOEHRINGER INGELHEIM ANNOUNCE MAJOR COLLABORATION TO DEVELOP AND COMMERCIALIZE CERESTAT(TM)
AGREEMENT ON THE TRANSFER OF FERMENT ANIMAL HEALTH TO BOEHRINGER INGELHEIM
Ethical Holdings Plc Announces Major Agreement With Boehringer Ingelheim For Morphine Once-Daily Tablet
Boehringer Ingelheim Corporation Reaches Agreement with NOBL Laboratories
Boehringer Ingelheim Acquires Ben Venue Laboratories in the USA
Boehringer Ingelheim GmbH and Vion Pharmaceuticals Sign Worldwide License Agreement for Phase III Cancer Drug
Boehringer Ingelheim Completes Acquisition of Ben Venue Laboratories in the U.S.
Cambridge NeuroScience Will Not Restart Accrual in Stroke Trial
Boehringer Ingelheim GmbH International Acquires New HIV/AIDS Drug from Pharmacia & Upjohn.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters